Blood cancer trial sponsored by the University of Birmingham opens for recruitment

blood 900

A new Cancer Research UK-funded clinical trial being sponsored by the University of Birmingham has opened for recruitment aiming to investigate the efficacy of a novel treatment for patients affected by a specific type of blood cancer.

PROMise, which is being co-ordinated via the Cure Leukaemia-funded Trials Acceleration Programme (TAP) hub at the University of Birmingham’s Cancer Research UK Clinical Trials Unit (CRCTU), will recruit patients aged over 16 who suffer with myelofibrosis (MF).

Over the next two years, 15 NHS centres will recruit MF patients who will be given a novel agent called PLX2853 in addition to the existing standard treatment of ruxolitinib.

Each year in the UK over 300 patients are diagnosed with MF, which is a blood cancer associated with debilitating symptoms including extreme fatigue, pain, weakness and shortness of breath. Around 10-20% of MF patients go on to develop acute myeloid leukaemia (AML) and consequently, a diagnosis of MF has a huge impact on both length and quality of life, with median survival from the time of diagnosis being just two years for patients with high-risk disease.

The only curative therapy for MF is stem cell transplant; however, this is only suitable for a small minority of younger patients who don’t present with comorbidities (the effect of all other conditions an individual patient might have - physiological or psychological).

The current NHS standard of care for those unsuitable for stem cell transplant is treatment with ruxolitinib, approved for use in 2011 and currently the only therapy approved with an indication for MF.

Professor Pam Kearns, Director of the University of Birmingham’s CRCTU, said: “Whilst ruxolitinib is already in widespread clinical use, many patients do not achieve an adequate response. Significant residual symptoms remain in most patients thus there is a major unmet clinical need and the PROMise trial is addressing an urgent need for improved therapeutic approaches for MF patients.”

Chief Investigator, Professor of Haematology at University of Oxford, Adam Mead, said: “The PROMise study is a really exciting study that has just opened in the UK and will be opening across 15 centres. This is introducing a new treatment called PLX2853, in combination with ruxolitinib, for patients with MF. The impact on patients for this combination of treatments, I hope, will be improvement of their symptoms, improvement of their quality of life, without causing them side effects.”

PROMise aims to:

  1. Establish the dose of PLX2853, administered in combination with ruxolitinib, that is tolerable
  2. Assess the efficacy of the combination of PLX2853 and ruxolitinib for reduction of symptoms associated with MF
  3. Assess the safety of the combination of PLX2853 and ruxolitinib

Up to 60 patients will take part in PROMise, and Cancer Research UK will provide trial funding, while Plexxicon will provide financial support as well as free of charge investigational product PLX2853.

CEO of Cure Leukaemia James McLaughlin said: “Without Cure Leukaemia’s funds, this study would not be currently recruiting patients and giving them access to potentially life-changing treatment. This highlights why this network is so vital and why funds raised for Cure Leukaemia make a direct impact on the lives of the 38,000 people diagnosed with a form of blood cancer in the UK each year.”

Michelle Mitchell, Chief Executive of Cancer Research UK said, “Clinical trials like PROMise are essential if we are to find better treatments for rare cancers, especially where the current avenues of treatment are narrow, like with myelofibrosis. We look forward to seeing what these researchers learn over the next two years, and if a more effective and much needed treatment can be found for people with MF.”

Patients wishing to take part in this study should speak directly to their consultant.

Notes to Editors

  • For media interviews, please contact Emma McKinney, Communications Manager, University of Birmingham, on +44 7815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.
  • The University of Birmingham is ranked amongst the world’s top 100 institutions, and its work brings people from across the world to Birmingham, including researchers and teachers and more than 6,500 international students from nearly 150 countries.
  • Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Its pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years. Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years. Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured. Blood cancer is the fifth most common type of cancer in the UK and the third biggest cancer killer.
  • Founded in 2003 by Professor Charlie Craddock CBE and patients Graham Silk and Michael Woolley, Cure Leukaemia helps to bring pioneering drug and transplant treatments to blood cancer patients across the United Kingdom.
  • TAP is a network of UK NHS hospitals, linked by Cure Leukaemia-funded Research Nurses, and co-ordinated through the central hub at the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham. TAP is focused on accelerated delivery of early phase haemato-oncology clinical trials. TAP launched in 2012 and has since opened 22 clinical trials with over 1,400 NHS patients benefitting directly from novel therapies that would otherwise be unavailable to them. TAP has leveraged over £160m worth of free pharmaceutical products, delivered free of charge into the NHS, and has attracted millions of pounds worth of investment from charity partners and private industry.
  • Myelofibrosis (MF) is the development of fibrous or scar tissue inside the bone marrow which prevents blood cells from developing properly. Damage in the bone marrow leads to a decrease in production of blood cells, which is compensated for by the liver and spleen; however, they are not as efficient at making blood cells and so this can result in a lack of red blood cells leading to shortness of breath and anaemia, as well as other symptoms. MF can affect people of any age but usually affects middle-aged and older people with the average age at diagnosis being 65 years. Around 10 to 20 out of every 100 people (10 to 20%) go on to develop AML which is a type of blood cancer that makes it more likely to contract infections and harder to get over infections. AML affects around 3,200 people in the UK each year. Adults or children can get AML but it is most common in older people with more than 40% of new cases occurring in people aged 75 and over.